Please Wait.....
Report
Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2032
Market Report (24 hrs) I 2022-05-01 I 117 Pages I DelveInsight
DelveInsights Acute Respiratory Distress Syndrome- Epidemiology Forecast2032 report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Acute Respiratory Distress Syndrome Disease Understanding
Acute respiratory distress syndrome (ARDS) is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury. In ARDS, fluid builds up inside the tiny air sacs of the lungs, and surfactant breaks down.
ARDS may develop over a few days, or it can get worse very quickly. Usually, the first symptom of ARDS is shortness of breath. Besides, other signs and symptoms of ARDS are low blood oxygen, rapid breathing, and clicking, bubbling, or rattling sounds in the lungs when breathing.
ARDS is generally characterized by three stages such as exudative stage, fibroproliferative (or proliferative) stage, resolution, and recovery stage. The exudative stage is the accumulation of protein, excessive fluid and inflammatory cells in the alveoli occur in the exudative stage. This phase usually is seen within the first 2 to 4 days after the onset of lung injury. Fibroproliferative (or proliferative) stage is the proliferation of connective tissue and other structural elements in the lungs in response to the initial lung injury. The chances of a patient having pneumonia sepsis and rupture of the lungs are very high in this stage. Resolution and Recovery are in this stage, the lung reorganizes and recovers. During this stage, lung function may continue to improve in patients. The fourth phase of ARDS is also seen according to some experts in which when some patients due to acute illness have continued health problems while some may experience anxiety, depression, and flashback memories of their critical illness, which are very similar to post-traumatic stress disorder. This stage is still an area under research.
Acute Respiratory Distress Syndrome Diagnosis
Early recognition of ARDS is important for the timely initiation of lung-protective ventilation strategies. Even after attempts to improve the definition of the disease, ARDS remains under-recognized by clinicians. Oftentimes, when a diagnosis is made, it has been after a significant delay. The rate of under-diagnosis is reported to be as high as 40%, with higher rates of diagnosis with increasing disease severity. ARDS is a syndrome with several different clinical criteria that must be fulfilled; however, none of these data points is particularly precise. The current clinical criteria have low specificity, for example, 63% for the Berlin definition to identify DAD at autopsy. At present, no biomarker is present to aid in the diagnosis, and this is now an area of much active research.
Chest X-rays for the diagnosis of ARDS have relatively low sensitivity and specificity of approximately 70% when compared to CT scans. CXR performs better when the infiltrates are diffuse or patchy as opposed to focal. The use of CT scans and other imaging techniques in the diagnosis and management of ARDS has become increasingly important. Lung ultrasound is another modality that can be used as a bedside tool to facilitate the diagnosis of ARDS.
Continued in the report..
Acute Respiratory Distress Syndrome Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Acute Respiratory Distress Syndrome, severity-specific cases of Acute Respiratory Distress Syndrome, and incident cases of Acute Respiratory Distress Syndrome by risk factors scenario of Acute Respiratory Distress Syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Acute Respiratory Distress Syndrome Detailed Epidemiology Segmentation
Total incident cases of Acute Respiratory Distress Syndrome in the 7MM were found to be 1,187,682 cases in 2021. These cases are expected to change by 2032 at a CAGR of 1.5% during the study period (20192032).
Among 7MM, the United States has the highest number of incident cases of Acute Respiratory Distress Syndrome with 634,515 cases in 2021.
Assessments as per DelveInsights analysts show that in terms of severity-specific incidence, a similar trend is observed in all countries, with a majority of the cases pointing to moderate ARDS, except France, where severe cases of ARDS accounted for a maximum patient population.
In the United States, there were a total of 190,355, 295,684, and 148,477 severity-specific cases of mild, moderate, and severe Acute Respiratory Distress Syndrome respectively, in 2021. As per DelveInsights analysts, the severity-specific cases of Acute Respiratory Distress Syndrome will increase by 2032.
In EU-5, Germany has the highest number of incident cases of Acute Respiratory Distress Syndrome with 216,462 cases in 2021, followed by France with 115,168 cases and Italy with 72,878 cases. While the United Kingdom has the least number of cases with 36,976 in 2021.
In 2021, Japan had 73,039 incident cases of Acute Respiratory Distress Syndrome.
Scope of the Report
The report covers the descriptive overview of Acute Respiratory Distress Syndrome, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden of Acute Respiratory Distress Syndrome.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM, a total number of incident cases of Acute Respiratory Distress Syndrome, severity-specific cases of Acute Respiratory Distress Syndrome, and incident cases of Acute Respiratory Distress Syndrome by risk factors.
Report Highlights
11-Year Forecast of Acute Respiratory Distress Syndrome
The 7MM Coverage
Total incident cases of Acute Respiratory Distress Syndrome
Severity-specific Cases of Acute Respiratory Distress Syndrome
Incident cases of Acute Respiratory Distress Syndrome by risk factors
Key Questions Answered
What are the disease risk and burdens of Acute Respiratory Distress Syndrome?
What is the historical Acute Respiratory Distress Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
What would be the forecasted patient pool of Acute Respiratory Distress Syndrome at the 7MM level?
What will be the growth opportunities across the 7MM concerning the patient population with Acute Respiratory Distress Syndrome?
Out of the above-mentioned countries, which country would have the highest incident population of Acute Respiratory Distress Syndrome during the forecast period (20222032)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (20222032)?
Reasons to buy
The Acute Respiratory Distress Syndrome report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the 7MM Acute Respiratory Distress Syndrome epidemiology forecast.
The Acute Respiratory Distress Syndrome epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
The Acute Respiratory Distress Syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 20192032
1. Key Insights
2. Report Introduction
3. Acute Respiratory Distress Syndrome Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Acute Respiratory Distress Syndrome in 2019
3.2. Patient Share (%) Distribution of Acute Respiratory Distress Syndrome in 2032
4. Executive Summary of Acute Respiratory Distress Syndrome
5. Disease Background and Overview
5.1. Introduction of Acute Respiratory Distress Syndrome
5.1.1. Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
5.1.2. Development of Berlin Definition of ARDS
5.1.3. Problems with the AECC definition and subsequent Berlin definition of ARDS
5.2. Causes and Risk Factors
5.2.1. Risk Factors of Acute Respiratory Distress Syndrome
5.2.1.1. ARDS associated with Covid-19
5.3. Pathophysiology of Acute Respiratory Distress Syndrome
5.4. Stages of Acute Respiratory Distress Syndrome
5.5. Ventilator-Induced Lung Injury (VILI)
5.6. Diagnosis of Acute Respiratory Distress Syndrome
5.6.1. Differential Diagnosis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: 7MM
6.3.1. The United States
6.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)
6.3.3. Japan
6.4. Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM
6.5. The United States
6.5.1. Total Incident Cases of Acute Respiratory Distress Syndrome in the United States
6.5.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in the United States
6.5.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the United States
6.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
6.6.1. Germany
6.6.1.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Germany
6.6.1.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany
6.6.1.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany
6.6.2. France
6.6.2.1. Total Incident Cases of Acute Respiratory Distress Syndrome in France
6.6.2.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in France
6.6.2.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France
6.6.3. Italy
6.6.3.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Italy
6.6.3.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy
6.6.3.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy
6.6.4. Spain
6.6.4.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Spain
6.6.4.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain
6.6.4.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain
6.6.5. The United Kingdom
6.6.5.1. Total Incident Cases of Acute Respiratory Distress Syndrome in the UK
6.6.5.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK
6.6.5.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK
6.7. Japan
6.7.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Japan
6.7.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan
6.7.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan
7. Patient Journey
8. Key Opinion Leaders Views
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Table 1: Summary of Acute Respiratory Distress Syndrome Epidemiology (20192032)
Table 2: Definition of Acute Respiratory Distress Syndrome
Table 3: American European Consensus Conference Criteria for Acute Lung Injury (ALI) and the Acute Respiratory Distress Syndrome (ARDS)
Table 4: Berlin Definition of Mild, Moderate, and Severe Acute Respiratory Distress Syndrome (ARDS)
Table 5: Factors That Distinguish ARDS, CHF, and Pneumonia
Table 6: Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM (20192032)
Table 7: Total Incident Cases of Acute Respiratory Distress Syndrome in the US (20192032)
Table 8: Severity-specific Cases of Acute Respiratory Distress Syndrome in the US (20192032)
Table 9: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the US (20192032)
Table 10: Total Incident Cases of Acute Respiratory Distress Syndrome in Germany (20192032)
Table 11: Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany (20192032)
Table 12: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany (20192032)
Table 13: Total Incident Cases of Acute Respiratory Distress Syndrome in France (20192032)
Table 14: Severity-specific Cases of Acute Respiratory Distress Syndrome in France (20192032)
Table 15: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France (20192032)
Table 16: Total Incident Cases of Acute Respiratory Distress Syndrome in Italy (20192032)
Table 17: Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy (20192032)
Table 18: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy (20192032)
Table 19: Total Incident Cases of Acute Respiratory Distress Syndrome in Spain (20192032)
Table 20: Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain (20192032)
Table 21: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain (20192032)
Table 22: Total Incident Cases of Acute Respiratory Distress Syndrome in the UK (20192032)
Table 23: Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK (20192032)
Table 24: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK (20192032)
Table 25: Total Incident Cases of Acute Respiratory Distress Syndrome in Japan (20192032)
Table 26: Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan (20192032)
Table 27: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan (20192032)
Figure 1: Risk factors of Acute Respiratory Distress Syndrome
Figure 2: A simplified model of the pathogenesis of Acute Respiratory Distress syndrome
Figure 3: Effects of Mast Cell Activation
Figure 4: Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM (20192032)
Figure 5: Incident Cases of Acute Respiratory Distress Syndrome in the US (20192032)
Figure 6: Severity-specific Cases of Acute Respiratory Distress Syndrome in the US (20192032)
Figure 7: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the US (20192032)
Figure 8: Total Incident Cases of Acute Respiratory Distress Syndrome in Germany (20192032)
Figure 9: Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany (20192032)
Figure 10: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany (20192032)
Figure 11: Total Incident Cases of Acute Respiratory Distress Syndrome in France (20192032)
Figure 12: Severity-specific Cases of Acute Respiratory Distress Syndrome in France (20192032)
Figure 13: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France (20192032)
Figure 14: Total Incident Cases of Acute Respiratory Distress Syndrome in Italy (20192032)
Figure 15: Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy (20192032)
Figure 16: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy (20192032)
Figure 17: Total Incident Cases of Acute Respiratory Distress Syndrome in Spain (20192032)
Figure 18: Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain (20192032)
Figure 19: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain (20192032)
Figure 20: Total Incident Cases of Acute Respiratory Distress Syndrome in the UK (20192032)
Figure 21: Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK (20192032)
Figure 22: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK (20192032)
Figure 23: Total Incident Cases of Acute Respiratory Distress Syndrome in Japan (20192032)
Figure 24: Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan (20192032)
Figure 25: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan (20192032)
Figure 26: Patient Journey
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security